Skip to main content
. 2017 Aug 6;8(40):66925–66939. doi: 10.18632/oncotarget.19963

Figure 1. Summary illustrating our systematic approach to ovarian cancer biomarker discovery.

Figure 1

For this analysis, we chose to focus on serous ovarian cancer patients, with optimal de-bulking, and 5-years of follow-up data (N = 111). In this context, we evaluated the prognostic value of mitochondrial markers for predicting overall survival (OS), progression-free survival (PFS) and post-progression survival (PPS).